A systematic literature review to evaluate the cardiac and cerebrovascular outcomes of patients with Fabry disease treated with agalsidase Beta
Gavin Y. Oudit, Pronabesh DasMahapatra, Nicole Lyn, Florence R. Wilson, Adekemi Adeyemi, Chae Sung Lee, Ana Crespo, Mehdi Namdar · 2025
Read A systematic literature review to evaluate the cardiac and cerebrovascular outcomes of patients with Fabry disease treated with agalsidase Beta by Gavin Y. Oudit, Pronabesh DasMahapatra, Nicole Lyn, Florence R. Wilson, Adekemi Adeyemi, Chae Sung Lee, Ana Crespo, Mehdi Namdar (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11790562.txt.
Description
Gavin Oudit and seven co-authors systematically review two decades of evidence on agalsidase beta for the heart and brain outcomes of Fabry disease, in a two thousand twenty-five literature review. The enzyme replacement therapy is standard, but outcome data come from small studies.
Forty-one studies met the criteria. Heart wall thickness measures fell significantly in six studies over one to six years, and one imaging study showed cardiac mass dropping after a year. Composite cardiac event rates ran from about four to twenty-four percent across studies, and cerebrovascular events from zero to nineteen percent, both numerically below placebo rates. The authors conclude treatment may stabilize or regress cardiac changes.
Catalog record
| CREATOR | Gavin Y. Oudit, Pronabesh DasMahapatra, Nicole Lyn, Florence R. Wilson, Adekemi Adeyemi, Chae Sung Lee, Ana Crespo, Mehdi Namdar |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |